News | April 20, 2026
Pharma stocks face Q4 reality check amid global headwinds
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Subscribe To Our Newsletter & Stay Updated
